| Exchange Disseminated Time |
|Biocon Ltd has informed BSE regarding a Press Release dated September 16, 2010 titled "Biocon partners with Teleradiology Solutions for Clinical Trials Radiology"|
"Biocon, India's largest biotechnology company, entered into an agreement with Teleradiology Solutions, a pioneer of the domain in India, to provide teleradiology reporting services to Clinigene, Biocon's Clinical Research Organization, Teleradiology Solution's quality-driven reporting process and cutting edge technology platform have the potential to greatly benefit biotech and pharma companies, obviating delays in the completion of clinical trials by optimizing the radiology reporting process.
Clinical trials radiology is a unique class by itself. In clinical trials, the objective is to demonstrate formally the efficacy, safety and cost utility of a new therapy for regulatory approval, with the fewest patients and in the shortest time possible. Teleradiology Solutions offers pharmaceutical vendors, clinical research organizations, and biotechnology organizations the opportunity to shorten their development cycles by using TRS Clinical Trials Radiology Reporting service. The organisation offers quality reporting by radiologists experienced in RECIST (Response Evaluation Criteria In Solid Tumors) and WHO (World Health Organisation) measurement criteria.
According to Kiran Mazumdar-Shaw, Chairman &. Managing Director of Biocon Ltd, 'To achieve our main objective, Accelerating Clinical Research, we leverage on an adept mix of technology, experience and personal traits. Keeping in line with our mission, Teleradiology Solutions, given their impressive track record, was the partner of choice to meet our complex image analysis requirements. The signing of this agreement further endorses Bangalore as the hub of excellence, both in Biotechnology as well as in high end healthcare delivery to the world."
According to Dr Arjun Kalyanpur, MD and Chief Radiologists, Teleradiology Solutions, "For pharmaceutical and Biotechnology companies involved in drug development R&D, delays in the drug development cycle can be an issue of concern. These are in part related to delays in reporting of radiologic scans that are performed to confirm that the patient under treatment has responded positively to the drug being evaluated in the clinical trial. The delays are in turn related to the worldwide shortage of radiologists, estimated to be as high as 20% in some studies. We are happy to partner with Biocon and offer our services to ensure timely execution and quality evaluation for clinical trials in radiology."